Speaker :

Dr. Mansi Khanderia, Medical Oncologist, Bangalore

PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy  versus endocrine therapy alone for HR+/HER2- early breast cancer 

Author: Erica Mayer

 Citation: Annals of Oncology (2020) 31 (suppl_4): S1142-S121510

 101/annonc/annonc325

Phase III study of palbociclib combined with endocrine therapy (ET) in patients with  hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with  high relapse risk after neoadjuvant chemotherapy (NACT): First results from  PENELOPE-B

Author: Loibl S

Citation: SABCS 2020 GS1-02